SR One

SR One is the independent corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested in more than 150 companies and has a current portfolio of approximately 30 private and public companies. For more information, please visit www.srone.com